• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DVS Sciences raises $14.6 million

DVS Sciences raises $14.6 million

July 15, 2011
CenterWatch Staff

The Ontario Institute for Cancer Research (OICR) and DVS Sciences have announced DVS Sciences has completed a $14.6 million series A financing. DVS, a Toronto-based spinoff from the University of Toronto, invented and manufactures instrumentation that enables paradigm-shifting biological research with potential clinical applications that include personalized medicine.

The company was an early recipient of seed funding from OICR, an independent, not-for-profit corporation established by the McGuinty government in 2005.  

The Series A financing was led by 5AM Ventures. Additional investors included Mohr Davidow Ventures, Pfizer Venture Investments and Roche Finance.

The financing will allow DVS Sciences to create state-of-the art manufacturing facilities in Ontario, establish a distribution network and increase global sales of CyTOF. The instrument, conceptually similar to a flow cytometer, enables highly multiplexed biomarker analysis for scientific research, clinical trials and personalized medicine.

“We are now in a position to commercialize our innovative instrumentation and reagents that will foster the acceleration of medical research, enable personalized therapeutic diagnosis and prognosis, and transform drug discovery,” said Dr. Scott Tanner, president of DVS Sciences.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing